Last Price$33.90.6%
Market Cap$15.2B
LTM Gross margin
73.9%
5Y avg
70.5%
Biotechnology industry
median
68.0%
Stock quality & Intrinsic value
6/10
4.3% undervalued
Royalty Pharma plc Gross margin
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 100.0% | 100.0% | 97.9% | 92.4% | 43.8% | 95.8% | 99.0% | 99.7% | 76.2% | 100.0% |
Overvalued or undervalued?
Check the intrinsic value for RPRX
and see if it's the right time to invest.
Royalty Pharma plc (RPRX) Gross margin comparison analysis
General
LTM Gross margin
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Royalty Pharma plcRPRX
73.9%
(3.8%)
(43.7%)
37.9%
Median Peer Set
85.9%
18.9%
(47.6%)
0.4%
Incyte CorporationINCY
92.3%
14.8%
(94.0%)
0.8%
United Therapeutics CorporationUTHR
89.2%
23.6%
25.7%
41.5%
argenx SEARGX
86.8%
198.6%
(60.5%)
(24.1%)
Regeneron Pharmaceuticals, Inc.REGN
86.7%
8.3%
10.4%
31.1%
Vertex Pharmaceuticals IncorporatedVRTX
86.1%
11.7%
N/A
(4.9%)
Alnylam Pharmaceuticals, Inc.ALNY
85.6%
23.0%
(38.6%)
(12.4%)
Novo Nordisk A/SNVO
84.7%
24.9%
142.8%
34.8%
BioNTech SEBNTX
84.3%
(77.4%)
(89.7%)
24.4%
BeiGene, Ltd.BGNE
83.1%
73.7%
(56.5%)
(35.9%)
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
RPRX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1,652.4 0.0% | 1,877.4 13.6% | 1,597.9 (14.9%) | 1,794.9 12.3% | 1,814.3 1.1% | 2,122.0 17.0% | 2,289.5 7.9% | 2,237.2 (2.3%) | 2,354.6 5.2% | 2,264.0 (3.8%) |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 33.3 | 136.0 | 1,019.3 | 88.1 | 23.0 | 5.7 | 560.7 | 0.0 |
% margin | 1,652.4 100.0% | 1,877.4 100.0% | 1,564.7 97.9% | 1,658.9 92.4% | 794.9 43.8% | 2,033.9 95.8% | 2,266.5 99.0% | 2,231.5 99.7% | 1,793.9 76.2% | 2,264.0 100.0% |
| Operating Expenses | 790.0 | 1,086.3 | 658.2 | 430.4 | (808.9) | 527.0 | 858.7 | 1,314.3 | 862.4 | 971.0 |
| Research & Development Expenses (R&D) | 98.4 | 91.0 | 117.9 | 392.6 | 83.0 | 26.0 | 200.1 | 177.1 | 52.0 | 2.0 |
| Selling, General & Administrative Expenses (SG&A) | 121.4 | 69.5 | 106.4 | 61.9 | 103.4 | 182.0 | 182.8 | 227.3 | 249.7 | 237.0 |
% margin | 794.3 48.1% | 722.9 38.5% | 939.7 58.8% | 1,364.4 76.0% | 2,623.2 144.6% | 1,595.0 75.2% | 1,430.7 62.5% | 977.5 43.7% | 1,492.2 63.4% | 1,292.0 57.1% |
| Interest Income | 0.0 | 0.0 | 6.8 | 24.4 | 22.3 | 28.4 | 53.5 | 78.3 | 72.3 | 0.0 |
| Interest Expense | 224.4 | 238.9 | 247.3 | 280.0 | 268.6 | 157.0 | 166.1 | 188.0 | 187.2 | 226.0 |
| Pre-tax Income | 758.7 | 761.9 | 1,343.2 | 1,517.9 | 2,461.4 | 1,702.0 | 1,241.2 | 230.1 | 1,700.1 | 1,331.0 |
% effective tax rate | 177.3 23.4% | 196.0 25.7% | 542.7 40.4% | 433.4 28.6% | 349.3 14.2% | 1,147.0 67.4% | 762.4 61.4% | 187.2 81.4% | 0.0 0.0% | 472.0 35.5% |
% margin | 581.4 35.2% | 565.9 30.1% | 1,210.0 75.7% | 1,377.7 76.8% | 2,348.5 129.4% | 495.2 23.3% | 478.8 20.9% | 42.8 1.9% | 1,134.8 48.2% | 859.0 37.9% |
| EPS | 0.96 | 0.93 | 3.42 | 3.89 | 6.42 | 1.32 | 1.15 | 0.10 | 3.41 | 1.92 |
| Diluted EPS | 0.96 | 0.93 | 3.42 | 3.89 | 6.42 | 1.32 | 1.15 | 0.10 | 2.53 | 1.45 |
% margin | 862.4 52.2% | 1,069.0 56.9% | 973.0 60.9% | 1,397.7 77.9% | 2,647.1 145.9% | 1,683.5 79.3% | 1,453.7 63.5% | 928.6 41.5% | 1,887.3 80.2% | 1,292.0 57.1% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Royalty Pharma plc's Gross margin?
As of today, Microsoft Corp's last 12-month Gross margin is 73.9%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Gross margin for Royalty Pharma plc have been 75.8% over the past three years, and 74.1% over the past five years.
2) Is Royalty Pharma plc's Gross margin Good?
As of today, Royalty Pharma plc's Gross margin is 73.9%, which is higher than industry median of 68.0%. It indicates that Royalty Pharma plc's Gross margin is Good.